Effect of Medicare Dialysis Payment Reform on Use of Erythropoiesis Stimulating Agents

Publisher： John Wiley & Sons Inc

E-ISSN： 1475-6773|50|3|790-808

ISSN： 0017-9124

Source： HEALTH SERVICES RESEARCH, Vol.50, Iss.3, 2015-06, pp. : 790-808

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use and cost of erythropoiesis-stimulating agents in patients with cancer

By Daniel Gregory   Hurley Dana   Whyte Joanna L.   Willey Vincent   Wilson Marcus   Kallich Joel  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1775-1784

Informa Healthcare

Access to resources Recommend Favorite

Evaluation and Determinants of Underprescription of Erythropoiesis Stimulating Agents in Pre-Dialysis Patients with Anaemia

By  

Nephron Clin Pract, Vol. 108, Iss. 1, 2008-01 ,pp. : c67-c74

Karger

Access to resources Recommend Favorite

The Effect of Erythropoiesis-Stimulating Agents in Patients with Therapy-Refractory Autoimmune Hemolytic Anemia

By  

Transfusion Medicine and Hemotherapy, Vol. 41, Iss. 6, 2014-09 ,pp. : 462-468

Karger

Access to resources Recommend Favorite

Frequency of Administration of Erythropoiesis‐Stimulating Agents for the Anaemia of End‐Stage Kidney Disease in Dialysis

By  

NEPHROLOGY, Vol. 20, Iss. 9, 2015-09 ,pp. : 663-665

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of renal anaemia with erythropoiesis‐stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis

By  

NEPHROLOGY, Vol. 20, Iss. S4, 2015-12 ,pp. : 29-32

John Wiley & Sons Inc

Access to resources Recommend Favorite